News

Page 2 of 1212345...10...Last »
Jan
5
2016

AIM Executive Director Joins Panel on FDA and Patient Centeredness

Last month, AIM Executive Director Cynthia Bens spoke on a panel titled "FDA and Patient Centeredness: A Work in Progress" at the FDA/CMS Summit for Biopharma Executives in Washington, D.C. She was joined by representatives from Parent Project Muscular Dystrophy, the National Alliance for Caregiving, the National Health Council, and... Read more »

Dec
22
2015

Stakeholder Consultation on FDA User Fee Reauthorization Continues, AIM Represented

The U.S. Food and Drug Administration (FDA) held two meetings in December with representatives from patient and consumer advocacy organizations to discuss progress in its negotiations with industry on the sixth reauthorization of the prescription drug user fee program and the fourth reauthorization of the medical device user fee program.... Read more »

Jul
27
2015

AIM Executive Director Bens Testifies at PDUFA Meeting

​AIM’s Executive Director Cynthia Bens was invited by the U.S. Food and Drug Administration to participate on the patient advocacy panel during a July 15 meeting on reauthorization of the prescription drug user fee program  (PDUFA). At the meeting, Bens offered her... Read more »

Jul
27
2015

Sarcopenia to Be Addressed in an FDA PFDD Meeting

Sarcopenia has been chosen as one of eight conditions the U.S. Food and Drug Administration will hold patient-focused drug development (PFDD) meetings on in fiscal years 2016 and 2017. The FDA’s Center for Drug Evaluation and Research (CDER) chose sarcopenia after receiving more than... Read more »

Dec
17
2014

AIM Submits Revised ICD-10 Sarcopenia Code Proposal to CDC

... Read more »

Page 2 of 1212345...10...Last »